Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due ...
Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...
Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...
Each patient received a 50,000-cell suspension of RPESC-RPE-4W implanted under the macula ... of adults affected by dry AMD and geographic atrophy. We look forward to advancing our Phase 1/2a ...
As most of you know, our lead candidate OpRegen for patients with dry AMD with geographic atrophy is an allogeneic cell transplant comprised of RPE cells. OpRegen is delivered as a suspension to ...
From this, we found that treatment with zervimesine altered proteins and pathways strongly associated with geographic atrophy and macular degeneration ... “Retinal pigment epithelial (RPE) cells are ...
The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... of photoreceptors and retinal pigment epithelial (RPE) cells in the central portion of the retina ...
Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") ...
Serpiginous chorioretinopathy is a rare form of posterior uveitis that causes inflammation and subsequent atrophy of the choroid, RPE and retina. The disease typically starts near the optic nerve ...
From this, we found that treatment with zervimesine altered proteins and pathways strongly associated with geographic atrophy and macular ... pigment epithelial (RPE) cells are responsible for ...
Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight ... and retinal pigment epithelial (RPE) cells, the central portion of ...